P. Lakatos

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

Dennis M. Black, Ian R. Reid, Steven Boonen et al. · Journal of Bone and Mineral Research · 2011 · 695 citations · Full text

Medicine, Orthopedic Surgery, Bone Metabolism +10

Elevated Fibroblast Growth Factor 23 is a Risk Factor for Kidney Transplant Loss and Mortality

Myles Wolf, Miklos Z. Molnar, Ansel P. Amaral et al. · Journal of the American Society of Nephrology · 2011 · 284 citations · Full text

Medicine, Nephrology, Surgery +17

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

Socrates E. Papapoulos, Kurt Lippuner, Christian Roux et al. · Osteoporosis International · 2015 · 277 citations · Full text

Medicine, Endocrinology, Bone Metabolism +16

Characterization of and Risk Factors for the Acute-Phase Response after Zoledronic Acid

Ian R. Reid, Greg Gamble, Peter Mesenbrink et al. · The Journal of Clinical Endocrinology & Metabolism · 2010 · 250 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Time to onset of bisphosphonate‐related osteonecrosis of the jaws: a multicentre retrospective cohort study

PPL Fung, Giorgio Bedogni, Alberto Bedogni et al. · Oral Diseases · 2016 · 109 citations · Full text

Dentistry, Maxillofacial Surgery, Dentoalveolar Surgery +10